TREATMENT OF PORTAL HYPERTENSION AND RELATED CONDITIONS BY COMBINED INHIBITION OF THE VEGF AND PDGF SIGNALLING PATHWAYS

摘要

The present invention relates to the treatment and/or prevention of portal hypertension and manifestations related thereof, by the inhibition of both platelet-derived growth factorand vascular endothelial growth factor signalling pathways. Combinations of VEGF and PDGF signalling pathways inhibitors are disclosed for the treatment and/or prevention of portal hypertension, e.g. rapamycin and imatinib, sorafenib.